拉米导致耐药增加E抗体阳性的纤维化病人的HCC危险性

zasxz

High Risk of Liver Cancer in Anti-HBe Positive Liver Cirrhosis Patients with Lamivudine Resistance


The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine (Epivir-HBV) is well documented. However, its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known.

In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months.

Results

All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain.

During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of HBV resistance, generally showing aggressive behavior, and one in the nine long-term responder patients (P = 0.013).

Lamivudine resistance was the only independent predictor of hepatocellular carcinoma development.

Conclusions
The authors conclude, 揙ur study suggests that the occurrence of lamivudine resistance increases the risk of hepatocellular carcinoma in anti-HBe positive cirrhosis and warrants further research.?/span>

09/22/04

Reference
P Andreone and others. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. Journal of Viral Hepatitis 11(5): 439-443. September 2004.

[此贴子已经被作者于2004-9-22 19:09:43编辑过]

zasxz

22名小三阳病人用拉米治疗42月，都产生应答。但9到42月内59％产生病毒变异，其中11个不久产生HCC。拉米变异为HCC产生的独立预测因素。

zhangmy

zasxz团长，都是英文看不懂啊。能不能麻烦您把精髓部分翻译一下。

zasxz

已翻